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Abstract 
Background: Chronic migraine (CM) is a neurological disorder associated with substantial disability. Botulinum 
toxin type A (Botox) is an approved and effective preventive treatment option for adult patients with CM. Transcra-
nial magnetic stimulation (TMS) is an alternative treatment device delivering a brief pre-set magnetic pulse used for 
self-administration by the patient at home. Despite being available in a risk share scheme TMS is perceived to be more 
costly in the UK. The objective of this study was to analyse the incremental costs of TMS compared to Botox in refrac-
tory CM patients both for a UK individual funding request setting as well as for an average UK specialist center setting.
Methods: Cost impact results were derived from a decision-tree model simulating treatment pathways over 1 year. 
Costs were applied from the most recently available UK data sources. Sensitivity analysis was performed for all 
variables.
Results: Based on published utilisation data 45.5 % of CM patients would continuously receive Botox over 1 year, 
whereas 53.7 % of TMS patients would be still on treatment at the end of year one. Total costs of Botox treatment 
accrue to £2923 in an individual funding request NHS cost setting, whereas TMS treatment results in £1466 in the first 
year. Applying a time-based NHS cost setting expenditures accrue to £1747 for the Botox treatment and to £1361 for 
the TMS treatment. In both cost settings variation of cost assumptions did have a minor impact on the cost increment 
from Botox to TMS.
Conclusion: The current risk share based remuneration model of TMS allows the UK NHS to reimburse only the cost 
of those patients experiencing reduction in migraine days resulting in lower costs for treating migraine attacks. Treat-
ment of chronic refractory migraine using TMS implies a substantial cost reduction potential for the management of 
chronic treatment of refractory migraine patients compared to conventional Botox treatment.
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Background
Chronic migraine (CM) is a neurological disorder asso-
ciated with substantial disability (Blumenfeld et al. 2011; 
Bigal et  al. 2008; Harwood et  al. 2004; Munakata et  al. 
2009; Natoli et  al. 2010). CM is defined as experiencing 
headaches on at least 15 days per month for ≥3 months, 
where ≥8 of those days per month are with migraine 
(Headache Classification Committee of the International 
Headache 2013). Refractory CM is a long-term disease, 
affecting around 610,000 people alone in the UK (Natoli 
et al. 2010; Ahmed 2011). Patients with CM are impacted 
by lower health-related quality of life and are more likely 
to suffer from severe disability (Blumenfeld et  al. 2011; 
Harwood et  al. 2004; Munakata et  al. 2009; Lipton and 
Bigal 2003). This resulted in a low number of migraine 
prophylaxis trials as CM patients being considered to be 
too highly disabled and treatment resistant (Dodick et al. 
2010).
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Costs are related both to acute drug treatment as well 
as to prophylaxis and discontinuation is a relevant factor 
for the latter. CM patients consume more direct health-
care resources than those with episodic migraine, such 
as acute medication use, physician visits and hospitali-
sations, along with a significant reduction in workplace 
productivity (Blumenfeld et  al. 2011; Harwood et  al. 
2004; Munakata et al. 2009; Lipton and Chu 2009). Only 
few treatment options are available for refractory chronic 
migraine patients.
Botulinum toxin type A (Botox) is an approved and 
effective preventive treatment option for adult patients 
with chronic migraine (Aurora et al. 2011). Botox injec-
tions are administered intramuscularly by a trained phy-
sician to between 31 and 39 sites divided across 7 specific 
head and neck muscle areas every 12 weeks in a special-
ist outpatients hospital clinic setting. According to NICE 
guidelines eligible patients for Botox receive at least two 
consecutive cycles for treatment irrespective of whether 
they are responsive to treatment in the first cycle (NICE 
2012).
Non-invasive neuromodulation devices are alternative 
treatment options in acute and preventive migraine ther-
apy (Barbanti et al. 2015; Barker et al. 1985; Bhola et al. 
2015). Spring TMS™ uses portable, single pulse transcra-
nial magnetic stimulation technology. It is an approved 
and effective patient use device for both acute and pre-
ventive treatment of migraine. TMS technology was 
invented in the UK by the Royal Hallamshire NHS Hos-
pital and University of Sheffield demonstrating the first 
stimulator in 1985 (Barker et al. 1985). In results from a 
UK Post Market Pilot programme Spring TMS demon-
strated safety, efficacy and very good tolerability in acute 
migraine for daily and preventative treatment use (Bhola 
et  al. 2015). The Spring TMS™ device is placed against 
the back of the head for less than a second to deliver a 
very brief pre-set magnetic pulse. The magnetic field 
passes through the skull and tissue non-invasively and 
without discomfort to induce electrical currents along 
the cortex of the brain. Spring TMS™ is designed to be 
used for self-administration by the patient at home and 
requires minimal patient training.
The National Institute for Clinical Excellence (NICE) 
has approved TMS for clinical use through its Inter-
ventional Procedure Guidance (IPG) 477 January 2014. 
However, NICE has not yet completed a technology 
(cost) appraisal or issued a Technology Appraisal Guid-
ance (TAG). TMS is available under a risk sharing pro-
gramme in the UK, where the initial quarterly usage 
evaluates patient response to treatment. This first quar-
ter is financed by the supplier. The subsequent quarter 
usage is to be paid by the NHS only for those patients 
benefiting from TMS observed as a reduction in migraine 
day frequency and or severity.
TMS addresses current NHS strategy to deliver ser-
vices close to the patient and out of the hospital. The use 
of TMS supports Kings Fund first priority of self-man-
agement for commissioners to deliver a more efficient 
and effective system with improved outcomes for the 
patient including pain management.
However, the general perception about TMS among 
healthcare professionals and funding authorities is that 
the treatment is more expensive than existing therapies 
such as Botox and as a consequence many primary care 
physicians and migraine clinics have been reluctant to 
prescribe the device and have taken an Individual Fund-
ing Request route for TMS in exceptional cases. Hence, 
the objective of this cost analysis was to evaluate the 
incremental cost impact of TMS by comparing two real 
life treatment costs scenarios of Botox and TMS over 
1 year both from an individual funding request perspec-
tive as well as from an average time-derived bottom-up 
UK cost center setting.
Methods
Our analysis outlines direct costs that accrue over time 
in patients with chronic refractory headache using 
either the pharmacologic injections or the risk sharing 
device-based preventive TMS treatment. The present 
study employs a cost analytic approach (Drummond 
et  al. 2005). A decision analytic model was developed 
to outline the incremental cost impact of the risk-shar-
ing approach of TMS compared to the traditional cost-
ing approach of Botox based on two alternative UK NHS 
costing settings. Modeling was performed using Treeage 
2015.
Model design
The model assumes that after being considered eligible 
patients are treated consecutively over 5 cycles of Botox 
or four quarter of TMS unless patients discontinue treat-
ment (Fig.  1). Botox patients are assumed to be treated 
at least over 2 consecutive 12  week-cycles according to 
the currently applied treatment scheme in the UK. TMS 
patients are subject for discontinuation after the ini-
tial quarter. It is assumed that those patients continuing 
either on Botox or TMS will remain on treatment until 
the end of the year.
Outcome and treatment attrition
For both treatment alternatives a reduction in resource 
utilisation when experiencing headache days for those 
patients responding of 49  % for Botox and 47  % for 
TMS were assumed (Bhola et  al. 2015; Rothrock 2011). 
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Responder rates were assumed to be identical with con-
tinuation rates. Values were based on published UK trial 
data resulting in 45.5  % for Botox (Khalil 2015a) and 
53.7 % for TMS (Bhola et al. 2015).
Costs
In order to reflect potential NHS cost perspectives a bot-
tom-up costing both for a scenario based on an individual 
funding authorisation perspective as well as an average 
time-based NHS resource use were calculated: Specialist 
center published fees of £650 per cycle for administer-
ing treatment, drug costs and follow-up visits and £140 
for initial neurologist consultation were applied for the 
individual funding authorisation (Hull Royal Infirmary 
K-U-H 2012). For the time-derived cost setting the values 
were based on expert advice and NICE Botox appraisal 
values (NICE 2011). Hence, Botox resource consumption 
in the initial cycle would require 30 min specialists time 
resulting in £70.00 with unit cost of £2.33 applied (NICE 
2011; Curtis 2014). Administering TMS would require 
one follow-up 15  min visit in the first quarter resulting 
in £35.00 (Table 1). Treatment period prorated adminis-
tration and drug or device costs for the CM preventive 
treatment with either Botox or TMS were calculated for 
a maximum of 5 cycles and four consecutive quarters, 
resp. 12-weeks Botox drug costs of £276.40 (NICE 2011) 
and quarterly TMS costs of £450 (eNeura, Manufacturer) 
were applied.
Treatment cost components were covering costs for 
physician visits due to migraine, cost of hospital visits 
due to migraine, cost of emergency room visits due to 
migraine and symptomatic treatment costs per day with 
headache. UK specific resource use consumptions for 
standard treatment of CM patients were obtained from 
the International Burden of Migraine Study (IBMS) 
(Bloudek et al. 2012). Resource unit valuation was based 
on 2013 NHS tariff information if not stated differently 
either from the 2013–2014 tariff information spreadsheet 
or based on the PSSRU (Curtis 2014; Department_of_
Health 2013) (Table 1).
Sensitivity analyses
Deterministic one-way sensitivity analyses were per-
formed both for the individual funding request setting as 
well as for the time-derived NHS setting. Apart from one 
variable (where Botox drug costs in week 48 for the low 
value assumes a 50 % share for the first 6 weeks only) all 
other parameter were varied at 10 %. Sensitivity analyses 
have been reported in an incremental tornado diagram 
highlighting the impact of the assumptions on the poten-
tial incremental cost difference of the two preventive 
treatment choices in both settings.
Results
Based on the outlined assumptions 45.5 % of CM patients 
would continuously receive Botox over 1 year. 53.7 % of 
TMS patients would be still on treatment at the end of 
year one and are responding. Total costs of the Botox 
treatment accrue to £2923, whereas TMS treatment 
results in £1466 in the first year. Applying the time-based 
cost setting expenditures accrue to £1747 for the Botox 
treatment and to £1361 for the TMS treatment.
Sensitivity analyses
Sensitivity analyses are reported from an incremental 
cost perspective. The base case increment from Botox 
to TMS is −£1466 for the individual funding request 
setting and −£386 for the time-based setting. When 
varying values at 10 % in the individual funding request 
setting Botox drug costs were the most influential vari-
able (Range −£1386 to −£1547) followed by the cost 
for treating TMS responder (range −£1394 to −£1539) 
(Fig. 2).
The incremental changes due to variation of values in 
the time-based setting are most influenced when varying 
the drug costs of Botox (range −£467 to −£306) followed 
Fig. 1 Decision tree model for two alternative prophylactic treatment approaches in refractory chronic migraine patients in the UK
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by the cost for TMS per quarter (range −£459 to −£314) 
(Fig. 3).
Discussion
This cost impact analysis compares 12-weekly Botox 
injections versus on demand patient applied TMS appli-
cations in refractory chronic migraine patients. Total 
annual cost of a chronic migraine patient in the UK 
accrue to £3718 and would result into a total UK cost 
burden of £2.2 billion when assuming a prevalence of 
0.91  % (Bloudek et  al. 2012; Buse et  al. 2012). From a 
NHS UK perspective, a potential for cost reduction of 
£1466 per patient in an individual funding request setting 
and £386 in a time-based average NHS cost setting was 
observed.
Our cost calculations are in the range of other cost 
analyses in chronic refractory patients conducted in other 
countries. The Scottish Medicines Consortium reports 
an incremental cost of £1394 when treating CM patients 
in addition with Botox (Scottish Medicines Consortium 
Submission 2011). A US analysis calculated annual cost 
related to Botox treatment of 4902 US $, which is higher 
compared to both the individual funding request setting 
as well as the time-based average cost setting (Rothrock 
2011). A German economic analysis of chronic cluster 
headache treatment assessed a comparable cost decre-
ment of €414 for a non-invasive neuromodulatory tech-
nique in addition to standard of care (Morris et al. 2016)..
Resource consumption data related to the treatment of 
chronic migraine patients in real life are sparse. Estimates 
of medical resource use were drawn from the Interna-
tional Burden of Migraine Study (IBMS) (Blumenfeld 
et  al. 2011). Impact of assumptions on cost differences 
was tested with varying the underlying assumptions for 
all variables at 10 %, which resulted in only small devia-
tions from the base case highlighting savings for TMS. 
Even when pro-rating the 48-week Botox drug costs, 
resulting in a bisection of the Botox drug cost in the fifth 
cycle, the increment from TMS to Botox remains nega-
tive at £1404. Hence, the size of the incremental differ-
ences is very robust to realistic changes of all parameters.
TMS is available under a pay for performance scheme 
in the UK, where the initial test quarter is free and the 
following quarters only have to be paid for responders. 
Risk sharing approaches in healthcare are not appropriate 
in all settings. Schemes should have realistic time scales 
and low administrative burden and should be based on 
sound evidence (Adamski et al. 2010). The TMS scheme is 
Fig. 2 Incremental sensitivity analysis Botox versus TMS for individual funding request setting (increment from Botox to TMS in £; negative values 
indicate savings)
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straightforward and places no further administrative bur-
den on decision makers and hence is suitable for achiev-
ing cost reduction potentials in healthcare. However, 
there is presumably a low awareness of the risk sharing 
approach related to TMS, as still high cost perceptions 
anticipated for the non-drug treatment approach from a 
decision-maker point of view exist. Our analysis shows 
major cost reduction potentials for TMS user.
Our modelling might comprise some limitations: The 
current model does no account for potential differences 
in side effects, which are more pertinent with Botox 
being associated in a UK real-life setting with neck stiff-
ness (16  %), injection site pain (15  %) and ptosis (9  %) 
(Khalil et al. 2015b). TMS patients reported minor neu-
rologic symptoms only lasting up to 30 min after apply-
ing the first pulse (20 %) (Bhola et al. 2015). As with other 
cost analyses in CM patients our decision tree model only 
covers the initial year and hence those receiving a longer 
treatment period might not adequately be acknowledged.
A strength of our model is the focus on real life settings. 
Hence, with an individual specialist centre cost scenario 
and the most recent UK real life data selected our model 
in particular addresses the decision-maker’s information 
needs of choosing efficient treatment options for severely 
impacted chronic migraine patients. Our cost assump-
tions are conservative as the expertise for the evaluation 
of eligible chronic migraine patients and for the individ-
ual treatment management decisions still remains scare 
in the UK and hence might result even in higher resource 
utilisation in those centres not being experienced with 
severe chronic migraine patients. In the Hull special-
ist centre the management of those 254 patients treated 
with Botox from 2010 to 2013 (Khalil et al. 2015b) would 
have resulted in a cost reduction of £372,364 (individual 
funding request assumptions) or £98,044 (time-based 
average NHS assumptions) if having been treated initially 
with TMS.
Conclusion
Both Botox and transcranial magnetic stimulation pro-
vide effective treatment approaches in patients with 
treatment-refractory chronic migraine in UK settings 
(Bhola et  al. 2015; Khalil et  al. 2014). TMS is perceived 
to induce higher costs compared to the pharmaceutical 
approach. Our decision analytic model demonstrates 
that treatment of chronic refractory migraine using TMS 
implies a substantial cost reduction potential for the 
management of treatment of chronic refractory migraine 
Fig. 3 Incremental sensitivity analysis Botox versus TMS for time-based setting (increment from Botox to TMS in £; negative values indicate savings)
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patients compared to conventional BOTOX treatment. 
The current risk share based remuneration model of 
TMS allows the National Health Service (NHS) to bear 
only the cost of those showing reduction in migraine days 
resulting in lower costs. Risk sharing is a relevant and 
future-oriented approach to performance based man-
agement in healthcare systems. Particularly in unclear 
efficacy situations risk sharing is providing an efficient 
approach for paymasters in healthcare and thus manages 
to balance patient needs and budgets when introducing 
innovative treatments.
Authors’ contributions
BB drafted the manuscript and model. FA, TB and RB contributed to all section 
of the manuscript and reviews of the model. All authors read and approved 
the final manuscript.
Author details
1 Institute for Health Economics, Steinbeis-University, Berlin, Germany. 
2 Institute for Social Medicine, Epidemiology and Health Economics, Charité 
University Medical Center, Berlin, Germany. 3 eNeura Inc., Sunnyvale, CA, USA. 
4 Neurosciences Business Unit, Hull and Yorkshire Hospitals NHS Trust, Hull, UK. 
5 Hull York Medical School, Hull, UK. 
Acknowledgements
We would like to thank Dr. Jörg Burkowitz and PD Dr. Thomas Reinhold for 
contribution in earlier preparational activities.
Competing interests
BB and FA declare no competing interests. TB and RB are employees of eNeura 
Inc., Sunnyvale, California, US.
Funding
eNeura Inc., Sunnyvale, California, US funded the analysis by a restricted grant.
Received: 13 June 2016   Accepted: 27 July 2016
References
Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wen-
dykowska K et al (2010) Risk sharing arrangements for pharmaceuticals: 
potential considerations and recommendations for European payers. 
BMC Health Serv Res 10:153. doi:10.1186/1472-6963-10-153
Ahmed F (2011) Chronic migraine-diagnosing migraine. In: Diagnosing 
migraine. The Migraine Trust. https://www.migrainetrust.org/about-
migraine/types-of-migraine/chronic-migraine/. Accessed 30 Jan 2015
Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE 
et al (2011) OnabotulinumtoxinA for treatment of chronic migraine: 
pooled analyses of the 56-week PREEMPT clinical program. Headache 
51(9):1358–1373. doi:10.1111/j.1526-4610.2011.01990.x
Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G (2015) Non-
invasive vagus nerve stimulation for acute treatment of high-frequency 
and chronic migraine: an open-label study. J Headache Pain 16:61. 
doi:10.1186/s10194-015-0542-4
Barker AT, Jalinous R, Freeston IL (1985) Non-invasive magnetic stimulation of 
human motor cortex. Lancet 1(8437):1106–1107
Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M et al 
(2015) Single-pulse transcranial magnetic stimulation (sTMS) for the 
acute treatment of migraine: evaluation of outcome data for the UK 
post market pilot program. J Headache Pain 16:535. doi:10.1186/
s10194-015-0535-3
Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the popula-
tion: burden, diagnosis, and satisfaction with treatment. Neurology 
71(8):559–566. doi:10.1212/01.wnl.0000323925.29520.e7
Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ et al (2012) 
Cost of healthcare for patients with migraine in five European countries: 
results from the International Burden of Migraine Study (IBMS). J Head-
ache Pain 13(5):361–378. doi:10.1007/s10194-012-0460-7
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al 
(2011) Disability, HRQoL and resource use among chronic and episodic 
migraineurs: results from the International Burden of Migraine Study 
(IBMS). Cephalalgia 31(3):301–315. doi:10.1177/0333102410381145
Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC et al (2012) 
Chronic migraine prevalence, disability, and sociodemographic factors: 
results from the American Migraine Prevalence and Prevention Study. 
Headache 52(10):1456–1470. doi:10.1111/j.1526-4610.2012.02223.x
Curtis L (2014) Unit costs of health and social care 2014. The University of Kent, 
Canterbury
Department_of_Health (2013) Payment by Results 2013-14. In: Department_
of_Health (ed) https://www.gov.uk/government/collections/payment-
by-results-2013-14. GOV.UK Department of Health.
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB 
et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: 
pooled results from the double-blind, randomized, placebo-controlled 
phases of the PREEMPT clinical program. Headache 50(6):921–936. 
doi:10.1111/j.1526-4610.2010.01678.x
Drummond MF, Sculpher M, Torrance G, O’Brien B, Stoddart GL (2005) Meth-
ods for the economic evaluation of health care programmes. Oxford 
University Press, Oxford
Harwood RH, Sayer AA, Hirschfeld M (2004) Current and future worldwide 
prevalence of dependency, its relationship to total population, and 
dependency ratios. Bull World Health Organ 82(4):251–258
Headache Classification Committee of the International Headache 
Society (2013) The international classification of headache dis-
orders, 3rd edition (beta version). Cephalalgia 33(9):629–808. 
doi:10.1177/0333102413485658
Hull Royal Infirmary K-U-H, UK (2012) Chronic Migraine injection treatment 
available at Spire Hull and East Riding Hospital. Spire Hull and East Riding 
Hospital, Hull. http://www.spirehealthcare.com/hull/news/botox-for-
migraine-treatment/. Accessed 10 Feb 2016
Khalil M, Zafar HW, Quarshie V, Ahmed F (2014) Prospective analysis of the use 
of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; 
real-life data in 254 patients from Hull, UK. J Headache Pain. 15:54. 
doi:10.1186/1129-2377-15-54
Khalil M, Zafar H, Ahmed F (2015a) How long to continue Botox in chronic 
migraine patients? A two year follow up of 248 patients treated in Hull, 
UK. Annual Meeting of the International Headache Society, Valencia
Khalil M, Zafar H, Ahmed F (2015b) Hull prospective analysis of Onabotulinum-
toxinA (Botox)® in the treatment of chronic migraine; real-life data in 465 
patients; an update. International Headache Society (IHC), Valencia
Lipton RB, Bigal ME (2003) Chronic daily headache: is analgesic overuse a 
cause or a consequence? Neurology 61(2):154–155
Lipton RB, Chu MK (2009) Conceptualizing the relationship between chronic 
migraine and episodic migraine. Expert Rev Neurother 9(10):1451–1454. 
doi:10.1002/pmic.200800454
Morris J, Straube A, Diener HC, Ahmed F, Silver N, Walker S et al (2016) 
Cost-effectiveness analysis of non-invasive vagus nerve stimulation 
for the treatment of chronic cluster headache. J Headache Pain 17:43. 
doi:10.1186/s10194-016-0633-x
Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J et al (2009) 
Economic burden of transformed migraine: results from the American 
Migraine Prevalence and Prevention (AMPP) Study. Headache 49(4):498–
508. doi:10.1111/j.1526-4610.2009.01369.x
Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L et al (2010) Global 
prevalence of chronic migraine: a systematic review. Cephalalgia 
30(5):599–609. doi:10.1111/j.1468-2982.2009.01941.x
NICE (2011) Botulinum toxin type A for the prophylaxis of headaches in adults 
with chronic migraine. National Institute for Health and Clinical Excel-
lence, London
NICE (2012) Botulinum toxin type A for the prevention of headaches in adults 
with chronic migraine. In: Excellence NIfHaC (ed) NICE technology 
appraisal guidance. NICE, London
Rothrock JF (2011) Onabotulinumtoxin A for the treatment of chronic 
migraine. Headache 51(4):659–660. doi:10.1111/j.1526-4610.2011.01880.x
